The $2.5 billion idea to help New York hospitals in need

An article published earlier this week by Crain’s New York Business examined the two extremes of New York hospitals and a possible way to close that gap.

Some Brooklyn hospitals in the borough’s poorer neighborhoods are on the verge of closing down, the article explained. Without state subsidies, hospitals such as Kingsbrook Jewish Medical Center would have collapsed a long time ago.

“That’s a structural gap that’s almost impossible to solve on your own,” Linda Brady, MD, Kingsbrook Jewish Medical Center president and CEO, said, as quoted by Crain’s.

Meanwhile, many other hospitals in New York are doing well and wanting to expand. Yet the providers who have had success are reluctant to partner with troubled hospitals such as those in parts of Brooklyn. It’s too much of a risk, they say.

Kenneth Raske, a chief executive of the Greater New York Hospital Association, offered a potential solution to this situation: Pay $2.5 billion to the wealthiest hospital systems over the course of five years for them to take these struggling hospitals into “the new world.”

To read more about this idea, and what various players in the industry had to say about it, click the link below and read the full story at Crain’s New York Business:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.